ADTX Stock: What to Know About Aditxt, Inc.

ADTX is the stock ticker of Aditxt, Inc., a U.S. health-innovation company working on immune-related programs and early-stage biotechnology. It is a micro-cap stock that moves sharply on company news — which is exactly why it deserves a careful, facts-first look rather than hype.

This article is not financial advice and does not recommend buying or selling ADTX stock. It lays out what the company says it does, what stage its programs are at, and the risks that come with this kind of stock — so you can do your own research with open eyes.

What Aditxt, Inc. Is

Aditxt, Inc. describes itself as a social innovation platform focused on accelerating health innovations. It is a real, publicly traded company: its common stock trades on OTC Markets under the ticker ADTX (see the OTC Markets ADTX quote page). The company operates programs across autoimmunity, cancer, early disease detection, infectious disease, and women’s health.

Like most small biotech names, Aditxt is a development-stage company: its value rests on the future potential of its programs, not on established, predictable revenue.

Aditxt’s Key Programs

Immune monitoring (AditxtScore)

One of the company’s lead platforms is AditxtScore for Immune Intelligence, which the company describes as a system that measures immune biomarkers and produces a score reflecting the state of a person’s immune system — including immune competence, inflammation levels, and responses to infections or vaccines. The company positions this for personalized healthcare and clinical use, in a market shaped by the post-pandemic focus on immune health.

Apoptotic DNA Immunotherapy (ADI)

ADI is the company’s therapeutic program: a class of therapies designed to teach the immune system to tolerate specific antigens rather than attack them. The company has pointed to preventing organ transplant rejection without lifelong broad immunosuppression as a lead application, with autoimmune conditions such as Type 1 diabetes and vitiligo as longer-term areas of interest. This remains early-stage research — and in biotech, early-stage science fails far more often than it succeeds.

Pearsanta

Pearsanta, Inc. is a majority-owned subsidiary of Aditxt focused on consumer health and specialty pharmacy products — prescription and over-the-counter products intended to generate nearer-term revenue to help fund the company’s longer-term research. Whether that revenue materializes at a meaningful scale is something to check in the company’s filings rather than assume.

Illustration of an ADTX stock chart on a tablet in a modern office

Why ADTX Stock Carries High Risk

Before anything else, understand what kind of stock this is:

  • Micro-cap volatility. Small biotech stocks routinely swing double digits on single news items, and ADTX is no exception.
  • Clinical and regulatory risk. Early-stage programs can fail in trials or stall with regulators. Most experimental therapies never reach the market.
  • Financing and dilution risk. Development-stage biotechs typically fund operations by issuing new shares, which can dilute existing shareholders. The share-count trend and cash position in SEC filings tell the real story.
  • Execution risk. Moving from promising science to approved, revenue-generating products is a long, expensive road with many failure points.

None of this means the company will fail — it means the range of outcomes is wide, and the downside is real.

What to Research Before Considering ADTX Stock

If you want to go deeper, these are the documents that matter — not social-media sentiment:

  • The company’s latest 10-K and 10-Q filings on SEC EDGAR: cash on hand, burn rate, and share count.
  • Clinical-trial status for ADI and any updates on the Pearsanta business.
  • Any reverse splits, offerings, or warrant overhangs affecting the share structure.
  • How the stock has actually behaved around past news events — and whether trading volume supported the moves.

For context on how other speculative stock stories have played out, see our profiles of PLL stock (Piedmont Lithium) and JEPQ stock, and our look at MSN Money’s role in modern finance.

Frequently Asked Questions

Is Aditxt, Inc. a real company?
Yes. Aditxt, Inc. is a real, publicly traded U.S. company whose common stock trades on OTC Markets under the ticker ADTX.

What does Aditxt do?
It works on health-innovation programs, including immune monitoring (AditxtScore), an early-stage immunotherapy platform (ADI), and a consumer-health subsidiary (Pearsanta).

Does ADTX pay a dividend?
Development-stage biotech companies like Aditxt typically do not pay dividends; they reinvest available capital into research. Confirm the current status in company filings.

Why is ADTX stock so volatile?
Micro-cap biotech stocks trade on expectations about future programs rather than current earnings, so news, financing announcements, and thin trading volume can all cause sharp moves.

Has ADTX Been Delisted from Nasdaq?

Yes. ADTX no longer trades on Nasdaq. Nasdaq moved to delist the stock after it stayed under $1, and it now trades over the counter on OTC Markets under the same ticker, ADTX — in fact, on the OTC Expert Market, with warnings for delinquent SEC reporting and recent reverse splits. As of 13 November 2026, Google Finance showed a price of $0.00040 and a market capitalisation of about $208,000, against a 52-week high of $1,375.90. OTC Expert Market trading means less liquidity, wider spreads and less public information than a Nasdaq listing — which adds to the risk. See the OTC Markets ADTX quote page for the current status.

The Bottom Line

ADTX stock represents a small, early-stage health-innovation company with ambitious programs in immune science — and the full set of risks that come with that profile. It is the kind of stock where research matters more than narratives: read the filings, understand the actual stage of the programs, and weigh the real possibility of significant losses. This is educational information, not financial advice.

Jackson
Jackson

Jackson is the founder and editor of NowItsTrend, a site covering tech, lifestyle, world news and trending stories. He writes about what is trending and keeps readers up to date with clear, useful coverage of the topics people are searching for.

Articles: 378